Monthly Archives: September 2011

Nycomed and Almirall announce licensing agreement for ebastine in Asia

Nycomed and Almirall have announced that they have signed a licensing and supply agreement for Almirall’s antihistamine ebastina, under the trademark Kestine, indicated for allergic rhinitis and chronic idiopathic urticaria, in China and other key emerging markets. Under the terms … Continue reading

Leave a Comment

Filed under alliances

Graceway Pharmaceuticals files for bankruptcy protection

Graceway Pharmaceuticals, a maker of skin treatments and asthma medication, has sought bankruptcy protection with a plan to sell its assets to Galderma for $275 million. Graceway cited the loss of patent protection on Aldara, a cream used to treat … Continue reading

Leave a Comment

Filed under bankruptcy

Santen Pharmaceutical acquires Novagali Pharma

Santen Pharmaceutical, a Japanese pharmaceutical company, and Novagali Pharma, a French biopharmaceutical company specializing in ophthalmology and ocular therapeutics, have announced that Santen will acquire a controlling interest in Novagali. Santen develops ophthalmic products. Among prescription ophthalmic pharmaceuticals, Santen has … Continue reading

Leave a Comment

Filed under acquisitions

Neurosearch to cut workforce by 82.5% over the next two years in effort to conserve cash

Neurosearch has announced a restructuring and discontinuation of its other activities designed to conserve financial and management resources to complete the development of Huntexil its treatment for motor symptoms in Huntington’s disease. The company has adjusted its financial guidance from … Continue reading

Leave a Comment

Filed under funding

H. Lundbeck and Proximagen sign CNS collaboration

H. Lundbeck and Proximagen have announced that they have entered into a partnershipagreement designed to formalise a CNS-focused partnership between the two companies. As part of the Agreement, a steering committee involving representatives from both companies will focus on developing … Continue reading

Leave a Comment

Filed under alliances

Merck ends Johnson & Johnson joint venture

Merck has announced that it is selling its 50% interest in a joint venture with Johnson & Johnson over a collection of over-the-counter products, including the heartburn remedies Mylanta and Pepcid. Under the agreement, Merck will receive a one-time payment … Continue reading

Leave a Comment

Filed under joint ventures

Biotie Therapies merges with Newron in $63 million deal

Biotie Therapies has signed a deal to acquire Newron Pharmaceuticals for up to $63 million worth of shares. Newron has reported losses totaling about $60 million over the past two years. Newron ran into trouble in the spring of 2010 … Continue reading

1 Comment

Filed under acquisitions

Mesoblast and Lonza sign stem cell alliance

Mesoblast and Lonza have announced that they have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast’s off-the-shelf adult stem cell products. Under the agreement Lonza will supply Mesoblast’s clinical and long-term commercial Mesenchymal Precursor Cell … Continue reading

Leave a Comment

Filed under alliances

Vectura earns $5 million milestone payment from Novartis

Vectura has announced that NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist (LAMA) being investigated as a once-daily treatment for chronic obstructive pulmonary disease, has been filed by Novartis for marketing authorisation with the European Medicines Agency under the brand-name Seebri … Continue reading

Leave a Comment

Filed under alliances

Si-Bone closes $16 million Series C funding round

Si-Bone a medical device company focused on minimally-invasive approaches to sacroiliac joint disruptions and degenerative sacroiliitis, has announced that it has closed a $16 million Series C funding round. Participants include Montreux Equity Partners and Skyline Ventures.

Leave a Comment

Filed under funding